EUCTR2008-008857-53-GB进行中（未招募）1 期
Open-Label, Pilot Phase I/II Study of the Efficacy and Safety of Concomitant Megestrol + Formoterol in Patients with Cachexia and Advanced Malignancy
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 13
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Age greater than 18 years.
- •2.Tumour situation: any type of advanced (defined as locally recurrent or metastatic), incurable solid tumour, expected to remain without rapid progression in the next 8 weeks, and not likely to require new anti-neoplastic treatment, large field radiotherapy or major surgery.
- •3.Cachexia: Involuntary loss of weight of greater than or equal to 2% in 2 months or greater than or equal to 5% in 6 months, without (or with successfully treated) secondary causes of impaired oral nutritional intake (simple starvation).
- •4.No simple starvation: Participants must not be prevented from eating by severe structural barriers in the upper gastrointestinal tract or bowel obstruction. Participants with impaired ability to eat because of severe tumour caused symptoms (such as severe early satiety, anorexia, or taste alterations), but no severe structural damage of the gastrointestinal tract, are eligible.
- •5.Life expectancy greater than or equal to 3 months, in the judgment of the investigator.
- •6.Performance status less than or equal to 2.
- •7.Concomitant anti-neoplastic chemotherapy: allowed provided unchanged for previous 4 weeks and not causing = Grade II nausea, vomiting, mucositis or other GI tract toxicity.
- •8.Laboratory test results within these ranges: absolute neutrophil count = 1.5 x 109/L, serum potassium > 3.5mmol/L, serum creatinine = 180µmol, total bilirubin = 25µmol and AST (SGOT) and ALT (SGPT) = 2 x ULN or = 5 x ULN if hepatic metastases are present.
- •9. Diastolic blood pressure <95 mmHg.
- •10.No other trial: Participant has not participated in any other clinical trial within previous 28 days.
- •11.Women: A negative pregnancy test & effective contraception are mandatory for women of child-bearing age.
- •12.Gastrectomy: Participants with history of gastrectomy are eligible.
- •13.Voluntarily signed and dated Research Ethics Committee-approved consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. BMI > 30kg/m2, or gross fluid retention, including ascites (but presence of pleural effusion will not exclude the patient).
- •2. Parenteral nutrition.
- •3. High risk of failure to complete the study, as defined by laboratory finding of both Creactive protein > 10mg/L and white blood cell count > 11 x 109/L.
- •4. Uncontrolled diabetes mellitus or hyperthyroidism.
- •5. History of ongoing, significant ischaemic heart disease (specifically: myocardial infarction in the previous 3 months; coronary intervention in the previous 3 months; or unstable angina); clinically significant cardiac arrhythmias, especially third degree atrioventricular block; severe cardiac decompensation; idiopathic subvalvular aortic stenosis; hypertrophic obstructive cardiomyopathy; thyrotoxicosis; known or suspected prolongation of the QT interval (QTc > 0.44 sec for men or 0.46 sec for women).
- •6. An episode of lower limb thrombophlebitis within the previous two months; or a deep vein thrombosis within the previous six months; or a current documented prothrombotic tendency, e.g., protein C deficiency, marked thrombocythaemia.
- •7. Participants currently on treatment (or having been treated in the two weeks prior to screening) with any of the following agents or drug classes: other ß2-agonists or ß2-antagonists, unless given by the inhaled route, or other route in which systemic exposure is expected to be low; agents specifically intended to increase appetite or provide anabolic stimulus to muscles, e.g., growth hormone, anabolic steroids.
- •8. Participants with cerebral metastases or prophylactic whole brain irradiation for
- •possible cerebral metastases.
- •9. Known hypersensitivity to megestrol acetate or formoterol fumarate.
- •10. Known positive for HIV or infectious hepatitis B or C.
- •11. Pregnant or breast feeding females.
- •12. The presence in both legs of either a metal knee or metal hip implant.
- •13. Any of the standard contra-indications to MRI scanning.
- •14. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
研究者
相似试验
进行中（未招募）
不适用
A Phase I/II open label study to assess efficacy and safety of IPH1101 associated with low dose of interleukin 2, as add-on therapy to imatinib in CML patients with residual molecular diseaseChronic Myeloid LeukemiaMedDRA version: 9.1Level: LLTClassification code 10009700Term: CMEUCTR2007-004252-37-FRInnate Pharma
进行中（未招募）
1 期
A Phase 2, open-label study to assess the efficacy and safety of AK002 in patients with chronic urticaria who do not respond to anithistaminesPatients with different types of chronic urticaria resistant to standard dose antihistaminesMedDRA version: 20.0Level: PTClassification code 10052568Term: Urticaria chronicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2017-002581-51-DEAllakos Inc.48
招募中
1 期
An open label phase 1b/2 study to evaluate efficacy and safety of trastuzumab deruxtecan (T-DXd) plus nivolumab plus capecitabin plus oxaliplatin for patients with HER2 low gastric and gastroesophageal junction adenocarcinomaHER2 low gastric, gastroesophageal junction, or esophageal adenocarcinomaJPRN-jRCT2031230477Kohei Shitara31
进行中（未招募）
1 期
Open-Label Pilot Study to Evaluate the Efficacy of Palonosetron Associated with Aprepitant (Emend) and Dexamethasone in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy (HEC) - PALO-05-01This is a Phase 4, open-label, pilot study to evaluate the Efficacy of Plaonosetron associated with Aprepitant (Emend) and Dexamethasone in preventing nausea and vomitting in chemotherapy-naïve patients, 18 years or older receiving a Highly Emetogenic Chemotherapy (HEC) regimen containing cisplatin =70 mg/m2.EUCTR2005-002641-39-GBHelsinn Healthcare SA60
进行中（未招募）
不适用
A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination with Chemotherapy as First-line Therapy in Subjects with Advanced Gastric CancerEstudio de fase 2, abierto, de evaluación de la eficacia y la seguridad de telatinib en combinación con quimioterapia como tratamiento de primera línea en pacientes con cáncer gástrico avanzadoPatient population includes patients with Advance gastric cancer, with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. Patients must have measurable disease and must not have received prior systemic anticancer therapy for advance or metastatic gastric cancer.Indicación: Cáncer Gastrico AvanzadoMedDRA version: 9Level: PTClassification code 10061967Term: Gastric cancer stage IVEUCTR2009-010730-21-ESACT BIOTECH, Inc35